Clinical trials: Adverse Drug Events, active
Melanoma Stage III, Melanoma Stage IV
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV
- Trial name
- NCT04305145
- Testing
- Infliximab, Methylprednisolone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Drug Abuse, Harm Reduction
Harm Reduction Intervention for Anabolic-androgenic Steroids Users: a Randomized Controlled Trial
This clinical trial aims to investigate the short and long-term efficacy of a harm reduction intervention in reducing the use of non-clinical anabolic-androgenic steroids (AAS) in abusive users of AAS.
- Conditions
- Drug Abuse, Harm Reduction, Minimization, Harm, Anabolic Steroids Adverse Events
- Trial name
- SOS-RCT-HR (NCT07039539)
- Testing
- harm reduction intervention in non-clinical anabolic-androgenic steroids users
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Effect of Drug, Adverse Drug Event
Efficacy and Safety of Remimazolam Besylate for Sedation in Post-Non-Cardiac Surgery Patients Requiring Mechanical Ventilation
A multi-center, prospective, randomized, double-blind, active-controlled, no-inferiority clinical trial conducted across 5 tertiary medical centers in China.
- Conditions
- Effect of Drug, Adverse Drug Event, Mechanical Ventilation Complication, Critical Illness
- Trial name
- NCT06575530
- Testing
- Remimazolam Besylate, Dexmedetomidine Hydrochloride
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Beijing Shijitan Hospital, Capital Medical University
Psychiatric Disorder, Cognition Disorder
MEOP - Multidimensional Evaluations in Oncological Psychiatry
Cancer is among the leading causes of morbidity and mortality worldwide, profoundly affecting patients' lives at every level, and its psychological and psychiatric impacts remain a major concern.
- Conditions
- Psychiatric Disorder, Cognition Disorder, Treatment Compliance, Adverse Drug Event
- Trial name
- MEOP (NCT07406113)
- Testing
- Psychiatric and neuropsychological evaluation through rating scales
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ALL, Childhood, Pediatric Cancer
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL).
- Conditions
- ALL, Childhood, Pediatric Cancer, Toxicity, Drug, Adverse Drug Event
- Trial name
- MPGx-INDALL (NCT05512169)
- Where
- 2 sites in India
- Volunteers
- 556 people
- Sponsor
- University of Geneva, Switzerland
Fall, Fall Accident
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
The goal of this project is to determine whether pharmacogenomic testing (using participants' DNA) can help optimize medication prescribing and reduce side effects in older adults taking five or more medications.
- Conditions
- Fall, Fall Accident, Poly Pharmacy, Adverse Drug Events
- Trial name
- GREAT PHARM (NCT07216846)
- Testing
- DNA care pathway
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Florida Atlantic University
Acute Kidney Injury, Adverse Drug Event
Melatonin for Prevention of Kidney Injury
This study will evaluate the safety and effectiveness of melatonin for the prevention of antibiotic associated acute kidney injury in hospitalized patients.
- Trial name
- NCT05084196
- Testing
- Melatonin
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Rutgers, The State University of New Jersey
Blood Coagulation Disorder, Postoperative Blood Loss
Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery
Tranexamic axid is routinely used as an antifibrinolytic agent in cardiac surgery to reduce the risk of blood loss and transfusion.
- Conditions
- Blood Coagulation Disorder, Postoperative Blood Loss, Adverse Drug Event, Fibrinolysis; Hemorrhage
- Trial name
- NCT07164300
- Testing
- Tranexamic acid at a dose of 10 mg/kg followed by 1 mg/kg/h, Tranexamic acid at a dose of 20 mg/kg, Tranexamic acid at a dose of 30 mg/kg
- Where
- Greece
- Volunteers
- 150 people
- Sponsor
- University of Ioannina
Malignancy, Immune Related Adverse Events
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
Immunotherapies have improved cancer outcomes, but have a unique profile of immune-related adverse events (irAEs). Biorepositories have been established to collect data and samples to help improve our understanding of irAEs…
- Trial name
- NCT06789601
- Testing
- Informatics system for eligibility monitoring, Standard eligibility monitoring
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Brigham and Women's Hospital
Post Intensive Care Syndrome (PICS), Polypharmacy
The Critical Care Recovery Program: Use of a Structured Clinic Visit to Reduce Adverse Drug Events in ICU Survivors
Background and Objective: Intensive Care Units (ICUs) save lives, but many ICU survivors face ongoing health issues, including adverse drug events (ADEs) from medications started during their hospital stay.
- Conditions
- Post Intensive Care Syndrome (PICS), Polypharmacy, Adverse Drug Events, Critical Care, Intensive Care
- Trial name
- CCRP (NCT06723860)
- Volunteers
- 3,000 people
- Sponsor
- University of British Columbia
Oncolytic Virus, Diffuse Intrinsic Pontine Glioma
Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
This is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in…
- Conditions
- Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event
- Trial name
- NCT05717699
- Testing
- Ad-TD-nsIL12
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Capital Medical University
Oncolytic Virus, Diffuse Intrinsic Pontine Glioma
Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients…
- Conditions
- Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event
- Trial name
- NCT05717712
- Testing
- Ad-TD-nsIL12
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Capital Medical University
Esophageal Neoplasms, Adverse Drug Event
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer
This study is a randomized, open, parallel controlled clinical trial. The main purpose of this study was to compare the changes in body weight/body mass index (BMI) before and after treatment between the two groups of patients…
- Trial name
- NCT05800054
- Testing
- Nutritional Support Team, Docetaxel, cisplatin
- Where
- China
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University